Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 239
- Registration Number
- NCT05387031
- Locations
- 🇨🇳
Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Department of Gastroenterology, Chongqing Renji Hospital, University of Chinese Academy of Sciences, Chongqing, Chongqing, China
🇨🇳Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
A Multicentered Prospective Cohort Study of Chinese IBD Patients
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05386290
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 108
- Registration Number
- NCT05299931
- Locations
- 🇧🇪
Ingrid Arijs, Zaventem, Belgium
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT05270733
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT05252533
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Newport Huntington Medical Group, Huntington Beach, California, United States
A Study of Ustekinumab Treatment in Children With Crohn's Disease
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 545
- Registration Number
- NCT05242458
- Locations
- 🇺🇸
ImproveCareNow, Inc.,, Burlington, Vermont, United States
A Long-term Extension Study of Ustekinumab in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT05092269
- Locations
- 🇦🇷
Centro de Investigaciones Medicas Tucuman, San Miguel De Tucuman, Argentina
🇧🇪Huderf, Bruxelles, Belgium
🇧🇪Cliniques Universitaires Saint Luc, Bruxelles, Belgium
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05083182
- Locations
- 🇩🇰
Aarhus Universitetshospital, Arhus, Denmark
🇩🇰Odense Universitets Hospital, Odense, Denmark
🇫🇷CHU de Caen, Caen, France
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 182
- Registration Number
- NCT05029921
- Locations
- 🇨🇳
Ningbo medical center lihuili hospital, Ningbo, China
🇨🇳Huashan Hospital Fudan University, Shanghai, China
🇨🇳Shanghai 10th Peoples Hospital, Shanghai, China
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT04978493
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States
🇺🇸University of Utah Health Sciences Center, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.